Table 1.
Demographical characteristics and clinical data of the patients.
| Patient Characteristics | Number | Percentage | |
|---|---|---|---|
| Age | ≥56 | 91 | 56.2% |
| <56 | 71 | 43.8% | |
| Gender | Male | 100 | 61.7% |
| Female | 62 | 37.4% | |
| Tumor numbers | Single | 108 | 66.7% |
| Multiple | 54 | 33.3% | |
| Tumor size | ≤2.0 cm | 5 | 3.1% |
| 2.1–5.0 cm | 70 | 43.2% | |
| >5.0 cm | 87 | 53.7% | |
| Hepatis B surface antigen | Positive | 85 | 52.5% |
| Negative | 77 | 47.5% | |
| Hepatitis C virus antibody | Positive | 1 | 0.6% |
| Negative | 161 | 99.4% | |
| Platelet count (×109/L) | 242.8 ± 87.1 | ||
| Albumin (mg/dL) | 43.6 ± 3.7 | ||
| Alanine aminotransferase (U/L) | 35.4 ± 33.6 | ||
| Aspartate aminotransferase (U/L) | 32.6 ± 27.2 | ||
| Total bilirubin (umol/L) | 13.9 ± 19.9 | ||
| Prothrombin time (s) | 12.0 ± 4.9 | ||
| T stage | 1 | 89 | 54.9% |
| 2 | 58 | 35.8% | |
| 3 | 1 | 0.6% | |
| 4 | 14 | 8.6% | |
| N stage | 0 | 135 | 83.3% |
| 1 | 27 | 16.7% | |
| M stage | 0 | 153 | 94.4% |
| 1 | 9 | 5.6% | |
| AJCC TNM staging system | I | 82 | 50.6% |
| II | 41 | 25.3% | |
| III | 27 | 16.7% | |
| IV | 12 | 7.4% | |
| The number of elevated pretreatment serum liver tumor markers | 0 | 57 | 35.2% |
| 1 | 55 | 34.0% | |
| ≥2 | 50 | 30.8% | |
| Vascular invasion | Yes | 33 | 20.4% |
| No | 129 | 79.6% | |
| Microvascular invasion | Yes | 43 | 26.5% |
| No | 117 | 72.2% | |
| Unknown | 2 | 1.2% | |
| Nerve tract invasion | Yes | 30 | 18.5% |
| No | 130 | 80.2% | |
| Unknown | 2 | 1.2% | |
| Tumor differentiations | Well | 1 | 0.6% |
| Well-moderate | 1 | 0.6% | |
| Moderate | 45 | 27.8% | |
| Moderate to poor | 83 | 51.2% | |
| Poor | 21 | 13.0% | |
| Unknown | 11 | 6.8% | |
| Alpha-fetoprotein (25 ng/mL) | 421.9 ± 3664.4 | ||
| Cancer antigen 199 (35 U/mL) | 715.4 ± 2306.8 | ||
| Carcinoembryonic antigen (5 ng/mL) | 6.76 ± 19.6 | ||
| Protein induced by vitamin K absence or Antagonist-II (40 mAU/mL) | 400.7 ± 4112.3 | ||
| Alpha-fetoprotein (25 ng/mL) | Elevated | 20 | 12.3% |
| Normal | 142 | 87.7% | |
| Cancer antigen 199 (35 U/mL) | Elevated | 73 | 45.1% |
| Normal | 89 | 54.9% | |
| Carcinoembryonic antigen (5 ng/mL) | Elevated | 36 | 22.2% |
| Normal | 126 | 77.8% | |
| Protein induced by vitamin K absence or Antagonist-II (40 mAU/mL) | Elevated | 33 | 20.4% |
| Normal | 129 | 79.6% | |
| Hemoglobin, albumin, lymphocyte, and platelet score | 54.3 ± 30.1 | ||
| Neutrophil-to-lymphocyte ratio | 2.9 ± 2.8 | ||
| Platelet-to-lymphocyte ratio | 140.0 ± 66.6 | ||
| History of cholelithiasis | Yes | 30 | 18.5% |
| No | 132 | 81.5% | |
| Child–Pugh classifications | A | 160 | 98.8% |
| B | 2 | 1.2% | |
| Barcelona Clinic Liver Cancer staging | A | 100 | 61.7% |
| B | 20 | 12.3% | |
| C | 42 | 25.9% | |
| Recurrence | Yes | 94 | 58.0 |
| NO | 68 | 42.0% | |
| Intrahepatic tumor recurrence | Yes | 59 | 36.4% |
| NO | 103 | 63.6% | |
| Lymph node metastasis | Yes | 9 | 5.6% |
| NO | 153 | 94.4% | |
| Distant metastasis | Yes | 15 | 9.3% |
| NO | 147 | 90.7% | |